Professional Partners Inc./ Westcliff Compounding Pharmacy, Newport Beach, CA
Is Professional Partners Inc./ Westcliff Compounding Pharmacy registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Professional Partners Inc./ Westcliff Compounding Pharmacy hold a California pharmacy license?
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.
Has Professional Partners Inc./ Westcliff Compounding Pharmacy had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Apr 5, 2017) for Professional Partners Inc./ Westcliff Compounding Pharmacy. State board actions: no California State Board of Pharmacy action under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Professional Partners Inc./ Westcliff Compounding Pharmacy
- Location
- Newport Beach, CA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 5, 2017
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 8 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Professional Partners Inc./ Westcliff Compounding Pharmacy, a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Apr 5, 2017 | State referral letter | Referral Letter to the California State Board of Pharmacy Issued 04/05/2017 | FDA copy (archived) |
| May 9, 2016 | Form 483 | 483 Issued 05/09/2016 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Professional Partners, Inc./ Westcliff Compounding Pharmacy, Newport Beach, CA (FEI number 3012266548), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| May 9, 2016 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012266548 | 974716 |
Form 483s FDA has published for this site
- Jun 6, 2016: Form 483 to Professional Partners, Inc./ Westcliff Compounding Pharmacy, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Apr 20, 2016 to May 9, 2016: 8 observations
- Firm on the cover
- Professional Partners, Inc. / Westcliff Compounding Pharmacy, 1901 Westcliff Dr. Ste. 3A, Newport Beach, CA 92660-5505
- FEI number
- 3012266548
- Establishment type on the cover
- Producer of Sterile Drugs
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Drug product containers and closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
Specifically, your firm
does not have a written procedure to test containers and closures to ensure that they are pyrogen free:
has not conducted studies to show that sterile products' container/closures that are purchased non-sterile and sterilized by your firm are free of pyrogen after sterilization.
has not established written procedure for washing ·and depyrogenating of container and closures
used to hold sterile Testosterone hormone pellets. Currently, glass vials and REDACTED B4
caps a re REDACTED
B4 and t hen REDACTED B4.
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
Specifically, your firm has not conducted any validation study to show that REDACTED B4 is adequate to sterilize Testosterone hormone drug products.
Observation 3
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
approximately~
61~terile
Specifically, your firm has produced and distributed Testosterone hormone pellets in various strengths since January 6, 2016 without testing for endotoxin prior to distribution of the product.
Observation 4
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
SOP Nos. 19.004, Environmental surface and air testing and 16.009, LAFW (Laminar Flow Workbench) and REDACTED B4 are deficient in that they require that viable air and surface samples to be taken REDACTED B4 as is for ISO 5 REDACTED B4 instead of production days. Your firm also failed to perform routine environmental monitoring for March and April of 2016 on REDACTED B4 (ISO 5). The REDACTED B4 was used for compression of Testosterone pellets prior to REDACTED B4 sterilization.
Observation 5
Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically, the firm does not follow SOP No. 6. 00 I titled "Glassware-cleaning", for cleaning of REDACTED B4 SOP No. 6.001, section A.2, "Water-insoluble"; states: REDACTED B4. On April 25, 2016, I observed that the technician wiped the REDACTED B4 which was used in production of Testosterone Hormone pellets lot # 042520 16@5, with REDACTED B4
Technician REDACTED B7C, B6 stated that REDACTED B7C, B6 used non-sterilized REDACTED B4 for sanitization of the containers prior to use. REDACTED B7C, B6 also explained that REDACTED B7C, B6 sprayed the items with REDACTED B4 and let them REDACTED B4.
The same REDACTED B4 is used for REDACTED B4 of potent (Testosterone, Progesterone, Estradiol, etc.) and non-potent (Lidocaine, Baclofen, etc.) drug products.
Observation 6
Written records are not always made of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications.
Specifically, the firm has no written procedure to conduct investigation on unexplained discrepancies. For example, firm rejects some pellets after sterilization for Testosterone lots # 03302016@4, 01142016@18, 02092016@5, and 02012016@4; but failed to conduct any investigation to determine the cause for the rejection.
Observation 7
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, there is no written stability testing program to support the Beyond Use Date (BUD) of drug products. For example, sterile Testosterone hormone drug products are assigned with six months expiration date without a six months stability data on sterility.
Observation 8
The calibration of instruments, apparatus and recording devices is not done at suitable intervals in accordance with an established written program.
Specifically,
SOP Nos.: 6.013 REDACTED B4 Balance Cleaning and Maintenance"; 6.013.01, "REDACTED B4 Balances"; 6.0 I 3.02, REDACTED B4 Balance"; and 6.0 13.03, REDACTED B4 Balance" requiring balances to be calibrated with REDACTED B4 recorded on a balance Calibration log on are not followed. Firm uses only REDACTED B4 for calibration of all balances. 1
Your firm uses none-calibrated equipment and instruments for processing and measuring of the processes. The following pieces of equipment were used by your firm without calibration:
l(REDACTED B4 used for sterilization of Testosterone hormone pellets
lREDACTED B4 on incubator used for incubation of REDACTED B4 and contact plates (personnel fingertip samples)
REDACTED B4 used for verification/calibration of REDACTED B4 balance
REDACTED B4 used for monitoring REDACTED B4 cleanrooms (ISO 5 and 7).
State board of pharmacy records
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- California State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.